Fluorescence-Guided Surgical Debridement of Chronic Osteomyelitis
Utilizing Doxycycline Bone Labeling: A Technical Trick Revived
Garrhett G. Via,

Pre,1mler Health1

1Wright

1
MD ;

1
MD ;

David A. Brueggeman,
Grant M. Slack,
Jennifer L. Jerele, MD1

2
BS ;

James M. Danias,

3
DO ;

State University Department of Orthopaedic Surgery, Dayton, OH. 2Wright State University Boonshoft School of Medicine, Dayton, OH. 3Ortho NorthEast, Fort Wayne, IN.

Boonshoft School of Medicine, Medical Student Research Symposium, Dayton, OH, April 2021

WRIGHT STATE

ORTHO

Introduction:

Case Series:

Case Series Continued:

Discussion:

• Recalcitrant infections of bone and soft tissue are
commonly encountered by orthopaedic surgeons.

• Intraoperative sample photos are included depicting
bone fluorescence.

• Figure 3:

• Treatment strategies include long-term antibiotic
administration for suppression and/or surgical
debridement to obtain source control.1

• Figure 1:

• The senior author of this manuscript prefers
preoperative administration of 100 mg BID
doxycycline for at least 1 month combined with the
usage of an ordinary blacklight as the intraoperative
excitation source.
• The use of an ordinary blacklight is cost-effective,
readily attainable, and proven to be efficacious.7

• Intraoperatively identifying living, viable bone can be
challenging.

• A ilmitation of the work is that lack of quantitative
fluorescence measurements. It is hoped that any
curious surgeon merely gives this technical trick an
opportunity to demonstrate its worth.

• Debridement to bleeding bone may not correlate with a
bone’s metabolic state.8-10
• Living bone is known to contain fluorophores (Tryptophan,
Tyrosine, Phenylalanine), which enable it to naturally
fluoresce.5,6

A) Intraoperative fluorescence of tibia noted pre-debridement.

• Bone Fluorescence is also achieved via the chelation of
tetracycline molecules within the inorganic mineral matrix
of bone.3,4

Surgical Technique:

• PMH: Recurrent skin abscesses.
• Presented in 2018 with vague leg pain.
• CT and MRI findings consistent with chroni
osteomyelitis and intramedullary abscess of the
tibia.
B) More complete fluorescence of the same tibia noted following
completion of debridement.

• Figure 2:

• Pre-op use of tetracycline allowing enough time for the
metabolite to be incorporated into live bone.

• Taken to the OR for I&D and cultures, which grew
MRSA.
• 5 days later, taken back to the OR for
gentamicin/vancomycin-coated intramedullary nail
and gentamicin/vancomycin-impregnated cement
placement.
• She was discharged on IV daptomycin and PO
doxycycline 100mg BID.

• Doxycycline dosing can range from an IV formulation of
100 mg delivered in pre-op holding to a multi-week
regimen in an oral formulation of 100 mg BID.

• 7 weeks later returned for repeat I&D with bone
grafting of her tibia.

• OR lights turned off and a non-sterile team member uses
a blacklight to illuminate the surgical field.

• Intraoperatively, OR lights were shut off and a
black light was used to illuminate the wound.

• The intensity of fluorescence will be in stark contrast to
any non-viable areas of bone.
• Operations including ORIF, IM nailing, placement of
antibiotic-laden cement/beads into a bone defect to stage
for an additional procedure (i.e. Masquelet), can be done
per clinical scenario.

• More formal trials to objectively quantify
fluorescence intensity should follow.

Case Example: 30 YO F

• The quantity of healthy osteocytes correlates with visible
fluorescence. Thus, fluorescence can be used to
demarcate viable bone.11-13
• A form of this technique was originally described in 2002
and has not been presented since that time.2

Specimen of fresh-frozen cadaveric humerus with blacklight
exposure. Notice that minimal to no fluorescence is
exhibited by non-viable, dead bone.

• All exposed bone fluoresced, indicating live bone
with no need for further debridement or resection.
Demonstrated is a live, viable tibia with bone fluorescence noted
intraoperatively. This patient had not received any preoperative
doxycycline.

• At 1 year follow up, there was no tenderness over
the tibia with full ROM and no complaints.

Conclusion:
• The present manuscript has revived the concept of
fluorescence-guided bone debridement based
upon the biochemistry of bone labelling by
tetracyclines.
• Preoperative administration of doxycycline in a
patient with osteomyelitis may allow for increased
efficacy in guiding the surgical debridement
procedures.
• Variations in the technique do exist and can
function quite well, however the concept of bone
labelling for fluorescent-guided resection of chronic
osteomyelitis can be a useful tool in these
challenging cases.
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